Keeping Track: Imbruvica Snags First-Line CLL Claim; Gilead TAF Strategy Advances
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
Gilead Buys Its Third Priority Review Voucher, But Is The Mania Over?
Just as the tulip craze eventually subsided, it appears the pharma industry's infatuation with priority review vouchers also may be waning, as Sarepta sells its voucher for only $125m.
Priority Review Vouchers Appear To Be Dropping In Price
Gilead spent less than $338m for the coupon entitling it to a speedier FDA review, down at least $12m from AbbVie's high-water purchase price almost a year ago.
Keeping Track: Label Expansion For AbbVie/J&J's Imbruvica, Theravance's Vibativ
The latest drug development news and highlights from our FDA Performance Tracker.